Pemigatinib in Chinese patients with advanced/metastatic or surgically unresecta
- This topic has 0 replies, 1 voice, and was last updated 2 years, 5 months ago by
.
Viewing 1 post (of 1 total)
-
Posts
-
Pemigatinib in Chinese patients with advanced/metastatic or surgically unresectable cholangiocarcinoma including FGFR2 fusion or rearrangement: Updated data from an open-label, single-arm, multicenter phase II study (CIBI375A201 study).
https://meetings.asco.org/abstracts-presentations/212069
Viewing 1 post (of 1 total)
- The forum ‘Clinical Trials’ is closed to new topics and replies.